{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:43:47Z","timestamp":1767991427766,"version":"3.49.0"},"reference-count":36,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["NIHR151892"],"award-info":[{"award-number":["NIHR151892"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,8,10]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>People who are immunocompromised have a poor biological response to vaccinations. This study aims to determine in patients with chronic lymphocytic leukaemia (CLL) if a 3-week pause in Bruton tyrosine kinase inhibitor therapy (BTKi) starting 1\u2009week before delivery of SARS-CoV-2 vaccine booster, improves vaccine immune response when compared with continuation of BTKi.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>An open-label, randomised controlled superiority trial will be conducted in haematology clinics in approximately 10 UK National Health Service (NHS) hospitals. The sample size is 120, randomised 1:1 to intervention and usual care arms. The primary outcome is anti-spike-receptor binding domain (RBD) antibody level at 3 weeks post-SARS-CoV-2 booster vaccination. Secondary outcomes are RBD antibody levels at 12 weeks postbooster vaccination, participant global assessments of disease activity, blood films, full blood count and lactate dehydrogenase levels, impact on quality of life, self-reported adherence with request to temporarily pause or continue BTKi, T cell response against spike protein and relative neutralising antibody titre against SARS-CoV-2 viral variants. Additionally, there will be an investigation of any effects in those given influenza vaccination contemporaneously versus COVID-19 alone.<\/jats:p>\n                    <jats:p>The primary analysis will be performed on the as randomised groups (\u2018intention to treat\u2019). The difference between the study arms in anti-spike-RBD antibody level will be estimated using a mixed effects regression model, allowing for repeated measures clustered within participants. The model will be adjusted for randomisation factor (first line or subsequent line of therapy), and prior infection status obtained from prerandomisation antinucleocapsid antibodies as fixed effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has been approved by Leeds East Research Ethics Committee and Health Research Authority (REC Reference:22\/YH\/0226, IRAS ID: 319057). Dissemination will be via peer-review publications, newsletters and conferences. Results will be communicated to participants, the CLL patient and clinical communities and health policy-makers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN14197181\">ISRCTN14197181<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-077946","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T22:31:52Z","timestamp":1695940312000},"page":"e077946","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn14197181","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-3666","authenticated-orcid":false,"given":"Vicki S","family":"Barber","sequence":"first","affiliation":[{"name":"Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Peckham","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelia","family":"Duley","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Francis","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"additional","affiliation":[{"name":"Academic Rheumatology, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Moss","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-6989","authenticated-orcid":false,"given":"Jonathan A","family":"Cook","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Oxford Clinical Trials Research Unit (OCTRU), University of Oxford, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen M","family":"Parry","sequence":"additional","affiliation":[{"name":"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2025121223430518000_13.9.e077946.1","unstructured":"CRUK . Chronic lymphocytic leukaemia (CLL) incidence statistics; 2022."},{"key":"2025121223430518000_13.9.e077946.2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am J Hematol"},{"key":"2025121223430518000_13.9.e077946.3","unstructured":"National Cancer Institute Surveillance, E. and End Results Programme . Cancer STAT facts: leukemia - chronic lymphocytic leukemia (CLL). Available: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html [Accessed 19 Jun 2023]."},{"key":"2025121223430518000_13.9.e077946.4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"2025121223430518000_13.9.e077946.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-0893-0","article-title":"Chronic lymphocytic leukaemia in 2020: the future has arrived","volume":"22","author":"Milne","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2025121223430518000_13.9.e077946.6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0609.2008.01114.x","article-title":"Disease burden of chronic lymphocytic leukaemia within the European Union","volume":"81","author":"Watson","year":"2008","journal-title":"Eur J Haematol"},{"key":"2025121223430518000_13.9.e077946.7","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600555819"},{"key":"2025121223430518000_13.9.e077946.8","unstructured":"HMRN Incidence . 2023. Available: hmrn.org\/statistics\/incidence"},{"key":"2025121223430518000_13.9.e077946.9","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"2025121223430518000_13.9.e077946.10","first-page":"374","article-title":"Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up","volume":"78","author":"Molica","year":"1993","journal-title":"Haematologica"},{"key":"2025121223430518000_13.9.e077946.11","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409056283"},{"key":"2025121223430518000_13.9.e077946.12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182006"},{"key":"2025121223430518000_13.9.e077946.13","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106366","article-title":"Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia","volume":"93","author":"Paneesha","year":"2020","journal-title":"Leuk Res"},{"key":"2025121223430518000_13.9.e077946.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0959-x"},{"key":"2025121223430518000_13.9.e077946.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965"},{"key":"2025121223430518000_13.9.e077946.16","doi-asserted-by":"crossref","first-page":"109046","DOI":"10.1016\/j.intimp.2022.109046","article-title":"A systematic review and meta-analysis of immune response against first and second doses of SARS-Cov-2 vaccines in adult patients with hematological malignancies","volume":"110","author":"Noori","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025121223430518000_13.9.e077946.17","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/ajh.26951","article-title":"Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV-2 booster vaccination in hematologic neoplasms","volume":"98","author":"Jim\u00e9nez","year":"2023","journal-title":"Am J Hematol"},{"key":"2025121223430518000_13.9.e077946.18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0884-z"},{"key":"2025121223430518000_13.9.e077946.19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008758"},{"key":"2025121223430518000_13.9.e077946.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(01)00149-2"},{"key":"2025121223430518000_13.9.e077946.21","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41375-020-01074-4","article-title":"Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma","volume":"35","author":"Zent","year":"2021","journal-title":"Leukemia"},{"key":"2025121223430518000_13.9.e077946.22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/bloodadvances.2021005998","article-title":"Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia","volume":"6","author":"Herishanu","year":"2022","journal-title":"Blood Adv"},{"key":"2025121223430518000_13.9.e077946.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-021-02115-1","article-title":"Restoration of the immune function as a complementary strategy to treat chronic lymphocytic leukemia effectively","volume":"40","author":"Moreno","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"2025121223430518000_13.9.e077946.24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S2213-2600(22)00186-2","article-title":"Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial","volume":"10","author":"Abhishek","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2025121223430518000_13.9.e077946.25","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"key":"2025121223430518000_13.9.e077946.26","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world Ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol"},{"key":"2025121223430518000_13.9.e077946.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01219-7","article-title":"Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia","volume":"15","author":"Parry","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025121223430518000_13.9.e077946.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.09.001"},{"key":"2025121223430518000_13.9.e077946.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"2025121223430518000_13.9.e077946.30","unstructured":"UK Health Security Agency . COVID-19 vaccination programme - documents relating to the COVID-19 vaccination programme. Crown,"},{"key":"2025121223430518000_13.9.e077946.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019896688"},{"key":"2025121223430518000_13.9.e077946.32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/bjh.18072","article-title":"International validation of the EORTC QLQ-Cll17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia","volume":"197","author":"Oerlemans","year":"2022","journal-title":"Br J Haematol"},{"key":"2025121223430518000_13.9.e077946.33","unstructured":"Duggan J , Otter A , Andrews N , et al . Evaluation of Roche Elecsys anti-SARS-CoV-2 S serology assay for the detection of anti-SARS-CoV-2 S antibodies, P.H. England: Crown, 2021."},{"key":"2025121223430518000_13.9.e077946.34","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(20)30634-4"},{"key":"2025121223430518000_13.9.e077946.35","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"2025121223430518000_13.9.e077946.36","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-077946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:43:22Z","timestamp":1765611802000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-077946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,28]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/bmjopen-2023-077946"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-077946","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]}}}